Pathology is moving beyond conventional slide examination as artificial intelligence becomes increasingly integrated into diagnostic and research workflows. AI-powered pathology tools can help specialists analyze tissue images, identify cellular patterns, quantify biomarkers, and manage large volumes of digital pathology data. The combination of whole-slide imaging, machine learning, computer vision, and cloud technologies is creating a more data-driven approach to pathology while supporting faster and more consistent analysis.

The Numbers Behind the Opportunity

• 2025 market size: USD 168.3 million 

• 2026 market size: USD 211.2 million 

• 2033 projected market size: USD 1,151.6 million 

• CAGR (2026–2033): 27.4% 

• North America share in 2025: 40.3% 

• Software share in 2025: 51.2% 

• Machine learning share in 2025: 35.7% 

• Drug discovery & research pathology share in 2025: 36.3% 

• Life sciences companies share in 2025: 47.5% 

Download a free sample copy of the AI in Pathology Market report to understand detailed coverage and inclusions in the final report

Why AI Is Becoming Important in Pathology

One of the biggest changes is the shift from manually reviewing individual slides toward digitally assisted analysis. Once pathology images are converted into high-resolution digital files, AI algorithms can examine them at scale and highlight areas that may require closer attention.

This does not simply add another software layer to existing pathology systems. It changes how information can be extracted from tissue samples. AI can assist with tumor detection, cell classification, tissue segmentation, biomarker quantification, and other image-intensive tasks.

For laboratories dealing with increasing workloads, these capabilities can help pathologists prioritize cases and spend more time on diagnostically complex work.

Software Is Becoming the Intelligence Layer

Software represented 51.2% of revenue in 2025, making it the largest component segment. The importance of software reflects the growing need for platforms capable of analyzing digital slides and converting image data into useful clinical or research insights.

Modern AI pathology platforms can combine image analysis with workflow management and decision-support capabilities. This creates opportunities for healthcare organizations to connect scanners, pathology information systems, AI algorithms, and reporting workflows within a single digital environment.

Machine Learning Moves From Experimentation to Application

Machine learning accounted for 35.7% of revenue in 2025. Its ability to recognize patterns across large datasets makes it particularly suitable for pathology, where subtle differences in tissue morphology can contain valuable diagnostic information.

Deep learning models can be trained to recognize features associated with tumors, cellular abnormalities, tissue structures, and disease characteristics. As datasets become larger and digital pathology adoption expands, machine learning is expected to become increasingly embedded in routine workflows.

Drug Research Is Another Major Opportunity

The drug discovery and research pathology segment generated 36.3% of revenue in 2025. Pharmaceutical and biotechnology companies are using pathology data to understand disease mechanisms, evaluate treatment effects, discover biomarkers, and support drug development.

AI can process large numbers of tissue images much faster than conventional manual approaches, making it useful for research environments where thousands of samples may need to be evaluated. Combining AI pathology with genomic and molecular information could further strengthen precision medicine and targeted drug development.

North America Holds the Strongest Position

North America accounted for 40.3% of revenue in 2025, supported by advanced healthcare infrastructure, strong investment in artificial intelligence, established pharmaceutical and biotechnology industries, and growing adoption of digital pathology.

The U.S. remains a major center for AI pathology innovation, with technology companies, healthcare institutions, and life sciences organizations investing in computational pathology and AI-enabled diagnostic platforms.

Asia Pacific, meanwhile, is emerging as an important growth opportunity as healthcare digitization accelerates and demand for advanced diagnostic technologies increases.

Looking for more specific insights? Customize this report to suite your business needs

Competitive Landscape

The AI in pathology industry is characterized by high innovation and a fragmented competitive environment, with established healthcare technology companies and specialized AI developers competing to expand their capabilities. Partnerships, product launches, platform integration, and strategic acquisitions are important competitive strategies. 

Key companies profiled by Grand View Research include

• Leica Biosystems Nussloch GmbH (subsidiary of Danaher)

• Koninklijke Philips N.V.

• F. Hoffmann-La Roche Ltd.

• PathAI

• Proscia Inc.

• Aiforia/ Aiforia Technologies PLC

• Ibex Medical Analytics

• Mindpeak GmbH

• Owkin, Inc.

• Tempus AI

• Indica Labs, LLC.

• Qritive

What Comes Next?

The next stage of AI in pathology will likely involve deeper integration rather than standalone AI tools. Pathology images could increasingly be analyzed alongside clinical, molecular, and genomic information to create more comprehensive disease profiles.

Cloud-based platforms, automated image analysis, multimodal AI, and improved interoperability could make computational pathology more accessible to hospitals, laboratories, and research organizations.

With the industry projected to reach USD 1,151.6 million by 2033, AI is moving from an emerging pathology technology toward an important component of the digital diagnostic ecosystem.